Lv45
634 积分 2025-04-03 加入
Global, regional and national burden of primary liver cancer by subtype
12天前
已完结
Elimination Half-Life of Drugs: Value and Limitations
26天前
已完结
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
1个月前
已完结
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
1个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已关闭
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已关闭
Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica
1个月前
已关闭
Gene Therapy Drugs Based on Synthetic Oligonucleotides
1个月前
已完结
皖公网安备34019202002308
